oral liposomal compounded glp-1/gip Oral GLP-1 Tablets oral liposomal compounded glp-1/gip Our

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

Chronic cold stress in Glp1r-/-Gipr-/-, Glp1r-/-Glp2r-/-, and Glp2r-/- mice revealed distinct and overlapping roles for GLP-1R and GLP-2R in the expansion of the intestinal absorptive surface area expansion in response to chronic cold stress.

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Equinox, Costco, and Hims are rehashing old tactics to profit off medications known as GLP-1s

Chronic diseases such as obesity and diabetes, cardiovascular and inflammatory bowel diseases (IBD) share common features in their pathology